Methadone

Methadone is a fully synthetic opioid analgesic and one of the longest-established medicines of its kind ^[1][3]. Like morphine and other opioids it works primarily by activating the mu-opioid receptor, but it is unusual in also blocking the NMDA receptor, a glutamate channel involved in pain signaling and in the development of tolerance ^[1][3]. The drug is manufactured as a racemic mixture of two mirror-image forms, of which the levorotatory isomer carries most of the opioid activity; in some countries the isolated levomethadone is used instead ^[1]. It is well absorbed by mouth and has a notably long half-life that varies widely between individuals, which allows once-daily dosing but also complicates safe prescribing ^[1][3].

Methadone was first synthesized in Germany in the late 1930s by the chemists Gustav Ehrhart and Max Bockmuhl, working at the Hoechst laboratories of IG Farben ^[1]. After the Second World War it was introduced in the United States as an analgesic, marketed under the name Dolophine ^[1]. Its role in addiction medicine was established in the 1960s, when Vincent Dole and Marie Nyswander in New York pioneered the use of daily methadone to stabilize people dependent on heroin, giving rise to the practice of methadone maintenance treatment ^[1].

Today methadone has two principal medical roles. As a maintenance therapy for opioid use disorder it is taken once daily to suppress withdrawal and craving, and it remains the best-researched of the opioid replacement treatments; systematic reviews find that it keeps patients in treatment and reduces illicit heroin use more effectively than approaches that do not use opioid replacement ^[1][2]. In pain management it is used chiefly as a second-line strong opioid, often when patients are switched from another opioid that is no longer providing a good balance of relief and side effects, and its NMDA-blocking action is thought to give it particular value in difficult neuropathic pain ^[3][4]. Because its pharmacology is complex, careful dose selection and monitoring are emphasized in both settings ^[3][5].

Methadone is a controlled substance; in the United States it is placed in Schedule II, and its use for addiction is generally restricted to certified treatment programs ^[1]. It is available as tablets, oral solution and concentrate, dispersible tablets, and injectable forms ^[1]. The main safety concerns are those common to strong opioids, above all dose-dependent respiratory depression, which is most dangerous in people who have not developed tolerance, together with the risk of dependence and a prolonged withdrawal syndrome ^[1][3]. Methadone can also prolong the heart's QT interval, which in susceptible people raises the risk of a serious arrhythmia called torsades de pointes, and its metabolism through liver enzymes makes it prone to drug interactions ^[1][3].

The big three risks with methadone are respiratory depression, overdose from accumulation, and heart-rhythm trouble. Its analgesic effect fades in hours, but the drug itself lingers for a day or more, and peak respiratory depression lands later and lasts longer than the pain relief; that mismatch means someone can redose while yesterday's dose is still climbing, so fatal overdoses often happen in the first week of treatment or after a dose increase rather than at the very start.

Methadone also prolongs the QT interval and can trigger torsades de pointes, a dangerous arrhythmia; the risk climbs with higher doses (often flagged above 100 mg per day), with low potassium or magnesium, and when it is stacked with other QT-prolonging drugs, so baseline and follow-up ECGs are standard practice and a QTc past about 500 ms usually means cutting the dose or stopping.

Expect the usual opioid side effects too; constipation, sweating, pinpoint pupils, drowsiness, low blood pressure, and a slowed heart rate. It causes physical dependence and a long, drawn-out withdrawal if stopped abruptly. The most lethal interactions are with other central nervous system depressants; combining methadone with benzodiazepines, alcohol, or other opioids sharply raises the chance of stopping breathing, and that mix shows up again and again in overdose deaths.

CYP inhibitors (some antifungals, certain antibiotics, several SSRIs, grapefruit) can push levels up, while inducers (rifampin, carbamazepine, phenytoin, efavirenz) can drop them and throw a stabilized patient into withdrawal. Methadone is a Schedule II controlled substance in the United States, and for opioid use disorder it is dispensed through regulated programs. Naloxone reverses an overdose, but because methadone outlasts a single dose of naloxone, repeat dosing and prolonged monitoring are often needed.

Methadone combined with benzodiazepines causes profound respiratory depression and is black-box warned; both drugs suppress the respiratory center, and co-use has resulted in fatal overdoses ^[6][7]. This is a pharmacodynamic interaction; their depressant effects add. Potent CYP3A4 inducers such as rifampin accelerate methadone metabolism, lowering blood levels and precipitating withdrawal symptoms in maintained patients.

Long-acting antiretroviral medicines used for HIV also interact via shared CYP-mediated clearance pathways, requiring adjusted dosing in patients on both ^[8]. Interactions not well-studied in the literature include methadone with tramadol (both are serotonergic and undergo CYP2D6 metabolism, raising seizure and serotonin syndrome risks), with anticholinergic medications (which slow gut motility and theoretically enhance methadone absorption), and with strong monoamine oxidase inhibitors.

Checking a whole stack? Run it through interactions + stacks.